vagal-nerve stimulation (VNS) has been shown to stop strychnine-induced seizures in dogs and phentylenetratol - induced seizures in rats
a commercial device is now available for use in human beings - this device is composed of a pulse generator, a bipolar lead to stimulate the nerve, and a programming wand and software with handheld magnets capable of switching the simulator on and off. The device is implanted to stimulate the left vagus nerve rather than the right - this is because stimulation of the left vagus nerve is less likely to result in cardiac effects
principle and predictable side effects included increased cough, alteration in voice and throat pain or discomfort. VNS has associated with ventricular asystole (1) and it is important to determine whether sudden death might be more frequent with this form of treatment
trial evidence has shown that VNS has an unequivocal although modest therapeutic effect against partial seizures
NICE state (3):
In adults:
vagus nerve stimulation is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults who are refractory to antiepileptic medication but who are not suitable for resective surgery. This includes adults whose epileptic disorder is dominated by partial seizures (with or without secondary generalisation) or generalised seizures
In children:
vagus nerve stimulation is indicated for use as an adjunctive therapy in reducing the frequency of seizures in children who are refractory to antiepileptic medication but who are not suitable for resective surgery. This includes children whose epileptic disorder is dominated by partial seizures (with or without secondary generalisation) or generalised seizures
Reference:
Tattum WO et al . Ventricular asystole during vagus nerve stimulation for epilepsy in humans. Neurology 1999; 52: 1176-80.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page